The LYCRA Company Previews Bio-Derived LYCRA ® EcoMade Fiber at ISPO
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel industry, announced today that it is promoting its bio-derived LYCRA® EcoMade fiber at ISPO, December 3 to 5. The company is showcasing samples featuring the renewable elastane in Hall A3, Stand 101, and offering visitors a fully immersive VR experience to learn about the product. It will also be featured in the Sustainability Hub (Hall A2) and is the subject of a presentation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241202374744/en/
UpFit Capsule Collection from LIVE! includes leggings, top, and jumpsuit that are made with bio-derived LYCRA® EcoMade fiber, providing exceptional comfort, fit, and flexibility with the added benefit of being a more sustainable fiber. (Photo: Business Wire)
Bio-derived LYCRA® EcoMade fiber won two ISPO Textrends Awards for Fall/Winter 2026/27. In the fibers and insulation category, this renewable elastane won a “Top 5 Award,” and a garment made with the same fabric was recognized as a “Selection” in the pants & tights category. The Brazilian activewear and swimwear brand LIVE! produced the fabric and leggings using preview samples of this highly anticipated fiber.
Launching in 2025, bio-derived LYCRA® EcoMade fiber will be the world’s first large-scale commercially available renewable elastane. The award-winning product previewed at ISPO contains 70 percent renewable content and is certified under the USDA Bio-Preferred Program. The fiber delivers equivalent performance to the original LYCRA® fiber, and no re-engineering of fabrics, processes, or garment patterns is required.
“We believe bio-derived LYCRA® EcoMade fiber represents an exciting future where we can make real, transformative change in the industry without sacrificing performance,” said Steve Stewart, The LYCRA Company’s chief brand and innovation officer. “We are thrilled to receive this recognition from ISPO and applaud our customer LIVE! for creating the award-winning fabric and garment.”
The LIVE! brand is renowned for its high-quality, sustainable apparel, and its UpFit Capsule Collection includes the ISPO award-winning leggings, Bermuda-length leggings, a top, and a jumpsuit. These garments made with bio-derived LYCRA® EcoMade fiber provide exceptional comfort, fit, and flexibility with the added benefit of being a more sustainable fiber.
“At LIVE!, we believe the future of fashion must balance innovation with environmental responsibility,” said Joice Sens, founder and creative director at LIVE!. “This collection embodies the spirit of LIVE! FUTURE, our sustainable innovation lab, and highlights the importance of partnerships like this one with the LYCRA® brand, enabling us to develop products that combine cutting-edge technology with reduced impact."
Steve Stewart is presenting “All In: The Power of Partnership” on ISPO’s Green Stage on December 4 at 16:00 CET. His presentation details how collaboration has been critical to commercializing bio-derived LYCRA® EcoMade fiber and bringing it to market.
Visit The LYCRA Company’s ISPO Event Page for show information and to discover the range of sustainable solutions fueling its exhibit: COOLMAX® and THERMOLITE® EcoMade fibers made from textile waste, and LYCRA® FiT400™ fiber designed for circularity, are made with the planet in mind. To learn more about bio-derived LYCRA® EcoMade fiber, visit this webpage for product information.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202374744/en/
Contacts
Izaskun Hernanz
izaskun.hernanz@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom